Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

27,278 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Exploiting the PI3K/AKT pathway for cancer drug discovery.
Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Hennessy BT, et al. Nat Rev Drug Discov. 2005 Dec;4(12):988-1004. doi: 10.1038/nrd1902. Nat Rev Drug Discov. 2005. PMID: 16341064 Review.
Critical role of lysophospholipids in the pathophysiology, diagnosis, and management of ovarian cancer.
Mills GB, Eder A, Fang X, Hasegawa Y, Mao M, Lu Y, Tanyi J, Tabassam FH, Wiener J, Lapushin R, Yu S, Parrott JA, Compton T, Tribley W, Fishman D, Stack MS, Gaudette D, Jaffe R, Furui T, Aoki J, Erickson JR. Mills GB, et al. Cancer Treat Res. 2002;107:259-83. doi: 10.1007/978-1-4757-3587-1_12. Cancer Treat Res. 2002. PMID: 11775454 Review.
Convergence of multiple signaling cascades at glycogen synthase kinase 3: Edg receptor-mediated phosphorylation and inactivation by lysophosphatidic acid through a protein kinase C-dependent intracellular pathway.
Fang X, Yu S, Tanyi JL, Lu Y, Woodgett JR, Mills GB. Fang X, et al. Mol Cell Biol. 2002 Apr;22(7):2099-110. doi: 10.1128/mcb.22.7.2099-2110.2002. Mol Cell Biol. 2002. PMID: 11884598 Free PMC article.
Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.
Cui X, Zhang P, Deng W, Oesterreich S, Lu Y, Mills GB, Lee AV. Cui X, et al. Mol Endocrinol. 2003 Apr;17(4):575-88. doi: 10.1210/me.2002-0318. Epub 2003 Jan 2. Mol Endocrinol. 2003. PMID: 12554765
Specific keynote: molecular therapeutics in ovarian cancer.
Mills GB, Fang X, Lu Y, Hasegawa Y, Eder A, Tanyi J, Tabassam FH, Mao M, Wang H, Cheng KW, Nakayama Y, Kuo W, Erickson J, Gershenson D, Kohn EC, Jaffe R, Bast RC Jr, Gray J. Mills GB, et al. Gynecol Oncol. 2003 Jan;88(1 Pt 2):S88-92; discussion S93-6. doi: 10.1006/gyno.2002.6692. Gynecol Oncol. 2003. PMID: 12586094 Review. No abstract available.
Evidence that phosphatidylinositol 3-kinase- and mitogen-activated protein kinase kinase-4/c-Jun NH2-terminal kinase-dependent Pathways cooperate to maintain lung cancer cell survival.
Lee HY, Srinivas H, Xia D, Lu Y, Superty R, LaPushin R, Gomez-Manzano C, Gal AM, Walsh GL, Force T, Ueki K, Mills GB, Kurie JM. Lee HY, et al. J Biol Chem. 2003 Jun 27;278(26):23630-8. doi: 10.1074/jbc.M300997200. Epub 2003 Apr 24. J Biol Chem. 2003. PMID: 12714585
Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades.
Lu Y, Yu Q, Liu JH, Zhang J, Wang H, Koul D, McMurray JS, Fang X, Yung WK, Siminovitch KA, Mills GB. Lu Y, et al. J Biol Chem. 2003 Oct 10;278(41):40057-66. doi: 10.1074/jbc.M303621200. Epub 2003 Jul 17. J Biol Chem. 2003. PMID: 12869565
Linking molecular diagnostics to molecular therapeutics: targeting the PI3K pathway in breast cancer.
Mills GB, Kohn E, Lu Y, Eder A, Fang X, Wang H, Bast RC, Gray J, Jaffe R, Hortobagyi G. Mills GB, et al. Semin Oncol. 2003 Oct;30(5 Suppl 16):93-104. doi: 10.1053/j.seminoncol.2003.08.011. Semin Oncol. 2003. PMID: 14613030 Review.
Mechanisms for lysophosphatidic acid-induced cytokine production in ovarian cancer cells.
Fang X, Yu S, Bast RC, Liu S, Xu HJ, Hu SX, LaPushin R, Claret FX, Aggarwal BB, Lu Y, Mills GB. Fang X, et al. J Biol Chem. 2004 Mar 5;279(10):9653-61. doi: 10.1074/jbc.M306662200. Epub 2003 Dec 11. J Biol Chem. 2004. PMID: 14670967
Targeting PI3K-AKT pathway for cancer therapy.
Lu Y, Wang H, Mills GB. Lu Y, et al. Rev Clin Exp Hematol. 2003 Jun;7(2):205-28. Rev Clin Exp Hematol. 2003. PMID: 14763163 Review.
27,278 results
Jump to page